A case of advanced breast cancer responding to low-dose 5'-DFUR

J. Koh; Y. Murayama; M. Sano; H. Katai; K. Maeda; S. Sakai; O. Yamamoto; M. Hashimoto; Y. Hosoda

A case of advanced breast cancer responding to low-dose 5'-DFUR

J. Koh, Y. Murayama, M. Sano, H. Katai, K. Maeda, S. Sakai, O. Yamamoto, M. Hashimoto, Y. Hosoda

International Medical Center

Research output: Contribution to journal › Article › peer-review

Abstract

A 69-year-old female patient with locally advanced breast cancer with multiple bone metastases (T(4c)N₂-M₁) was treated with 5'-DFUR after failure of tamoxifen treatment. The 5'-DFUR dose was limited to 600 mg per day, half the usual dose, because of its gastroenterological side effects. The primary tumor and metastatic axillar lymph nodes regressed three months after the start of treatment, and the complete remission of lesions was obtained in 16 months. Reduction of bone metastasis was confirmed by the disappearance of osteolytic lesion in the skull roentogenogram and the decrease of abnormal accumulation on the bone scintigram. Serum levels of CEA and ST-439 markedly reduced during the treatment as the disease regressed.

Original language	English
Pages (from-to)	1063-1066
Number of pages	4
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	19
Issue number	7
Publication status	Published - 1992

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{ce73eaba8403457a94fe15aff31e5c6f,

title = "A case of advanced breast cancer responding to low-dose 5'-DFUR",

abstract = "A 69-year-old female patient with locally advanced breast cancer with multiple bone metastases (T(4c)N2-M1) was treated with 5'-DFUR after failure of tamoxifen treatment. The 5'-DFUR dose was limited to 600 mg per day, half the usual dose, because of its gastroenterological side effects. The primary tumor and metastatic axillar lymph nodes regressed three months after the start of treatment, and the complete remission of lesions was obtained in 16 months. Reduction of bone metastasis was confirmed by the disappearance of osteolytic lesion in the skull roentogenogram and the decrease of abnormal accumulation on the bone scintigram. Serum levels of CEA and ST-439 markedly reduced during the treatment as the disease regressed.",

author = "J. Koh and Y. Murayama and M. Sano and H. Katai and K. Maeda and S. Sakai and O. Yamamoto and M. Hashimoto and Y. Hosoda",

year = "1992",

language = "English",

volume = "19",

pages = "1063--1066",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "7",

}

TY - JOUR

T1 - A case of advanced breast cancer responding to low-dose 5'-DFUR

AU - Koh, J.

AU - Murayama, Y.

AU - Sano, M.

AU - Katai, H.

AU - Maeda, K.

AU - Sakai, S.

AU - Yamamoto, O.

AU - Hashimoto, M.

AU - Hosoda, Y.

PY - 1992

Y1 - 1992

N2 - A 69-year-old female patient with locally advanced breast cancer with multiple bone metastases (T(4c)N2-M1) was treated with 5'-DFUR after failure of tamoxifen treatment. The 5'-DFUR dose was limited to 600 mg per day, half the usual dose, because of its gastroenterological side effects. The primary tumor and metastatic axillar lymph nodes regressed three months after the start of treatment, and the complete remission of lesions was obtained in 16 months. Reduction of bone metastasis was confirmed by the disappearance of osteolytic lesion in the skull roentogenogram and the decrease of abnormal accumulation on the bone scintigram. Serum levels of CEA and ST-439 markedly reduced during the treatment as the disease regressed.

AB - A 69-year-old female patient with locally advanced breast cancer with multiple bone metastases (T(4c)N2-M1) was treated with 5'-DFUR after failure of tamoxifen treatment. The 5'-DFUR dose was limited to 600 mg per day, half the usual dose, because of its gastroenterological side effects. The primary tumor and metastatic axillar lymph nodes regressed three months after the start of treatment, and the complete remission of lesions was obtained in 16 months. Reduction of bone metastasis was confirmed by the disappearance of osteolytic lesion in the skull roentogenogram and the decrease of abnormal accumulation on the bone scintigram. Serum levels of CEA and ST-439 markedly reduced during the treatment as the disease regressed.

UR - http://www.scopus.com/inward/record.url?scp=0026646329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026646329&partnerID=8YFLogxK

M3 - Article

C2 - 1385689

AN - SCOPUS:0026646329

SN - 0385-0684

VL - 19

SP - 1063

EP - 1066

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 7

ER -

A case of advanced breast cancer responding to low-dose 5'-DFUR

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this